| ₹ crore | Q1 FY27 | Q1 FY26 | Change |
|---|---|---|---|
| Revenue | 250 | 187 | +34.0% |
| EBITDA | 48.2 | 31.5 | +53.1% |
| EBITDA margin | 19.3% | 16.9% | +2.4 pts |
| Profit before tax | 23.1 | 14.2 | +62.1% |
| Net profit | 17.1 | 10.3 | +66.8% |
| EPS | ₹6.29 | ₹3.89 | +61.7% |
Amounts on the left scale in ₹ crore; per cent on the right, dashed. L = lakh crore, K = thousand crore. Touch the chart to read any period.
| Tap a line for its trend | Currentlast 12M | FY26Mar 2026 | FY25Mar 2025 | FY24Mar 2024 | FY23Mar 2023 | FY22 and earlierAlpha Plus |
|---|
| 5,991 | — | — | — | — | FY22 and earlierEvery year the company has filed comes with Alpha Plus. | |
| 4.9 | 4.9 | 5.0 | 12.2 | 94.3 | ||
| 1,330 | 1,330 | 566 | 394 | 362 | ||
| 7,316 | — | — | — | — | ||
| 926 | 862 | 778 | 691 | 686 | ||
| — | +10.9% | +12.6% | +0.7% | — | ||
| 154 | 138 | 136 | 110 | 112 | ||
| 16.6% | 16.0% | 17.5% | 15.9% | 16.3% | ||
| 124 | 110 | 109 | 87.2 | 95.4 | ||
| 35.6 | 28.8 | 34.8 | 35.7 | 50.0 | ||
| 3.8% | 3.3% | 4.5% | 5.2% | 7.3% | ||
| ₹13.48 | ₹10.90 | ₹13.20 | ₹13.51 | ₹18.94 | ||
| — | −17.5% | −2.3% | −28.7% | — | ||
| — | −231 | 196 | −29.2 | −30.4 | ||
| — | −556 | −318 | −303 | −104 | ||
| −787 | −787 | −122 | −332 | −134 | ||
From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.
In ₹ Crore except Per Share 12 Months Ending | FY23 31/03/2023 | FY24 31/03/2024 | FY25 31/03/2025 | FY26 31/03/2026 | Current/LTM TTM · last close | |
|---|---|---|---|---|---|---|
| Market Capitalization | — | — | — | — | 5,990.6 | |
| - Cash, Equiv & ST Investments | 94.3 | 12.2 | 5.0 | 4.9 | 4.9 | |
| + Total Debt | 362.2 | 393.5 | 566.0 | 1,329.9 | 1,329.9 | |
| Enterprise Value | — | — | — | — | 7,315.6 | |
| Revenue | 686.2 | 690.7 | 777.6 | 862.0 | 925.5 | |
| Growth %, YoY | — | +0.7 | +12.6 | +10.9 | — | |
| EBITDA | 111.6 | 110.1 | 136.3 | 137.6 | 154.0 | |
| Margin % | 16.27 | 15.93 | 17.53 | 15.96 | 16.64 | |
| EBIT | 95.4 | 87.2 | 108.5 | 110.1 | 124.1 | |
| Net Income | 50.0 | 35.7 | 34.8 | 28.8 | 35.6 | |
| Margin % | 7.28 | 5.16 | 4.48 | 3.34 | 3.84 | |
| EPS, Adj (current shares) | 18.94 | 13.51 | 13.20 | 10.90 | 13.48 | |
| Growth %, YoY | — | -28.7 | -2.3 | -17.5 | — | |
| Cash from Operations | -30.4 | -29.2 | 196.0 | -231.5 | — | |
| Capital Expenditures | -103.7 | -302.8 | -317.7 | -555.7 | — | |
| Free Cash Flow | -134.1 | -331.9 | -121.7 | -787.2 | -787.2 | |
Prices at the 29 October 2026 close · figures from the company's filings with NSE
NEOGEN CHEMICALS (NSE: NEOGEN) had a market capitalisation of ₹6,193 crore at the 29 October 2026 close (₹2,261.70 a share), a PE ratio of 174.1 on the last four quarters' profit and a price-to-book ratio of 7.59. In FY26 its consolidated net profit was ₹28.8 crore on revenue of ₹862 crore; in Q1 FY27 (April–June 2026) it was ₹17.1 crore, up 66.8% year on year. Its debt-to-equity ratio was 1.63 on 31 March 2026. Promoters held 48.31% of the shares on 30 September 2026.
NEOGEN CHEMICALS's PE ratio is 174.1 at the 29 October 2026 close (₹2,261.70 a share): a market capitalisation of ₹6,193 crore divided by consolidated net profit of ₹35.6 crore over the last four quarters (Q2 FY26 to Q1 FY27). On FY26 net profit (₹28.8 crore) it is 215.4.
NEOGEN CHEMICALS's debt-to-equity ratio was 1.63 on 31 March 2026: borrowings of ₹1,330 crore against total equity of ₹816 crore. A year earlier, on 31 March 2025, it was 0.72.
NEOGEN CHEMICALS's net worth — shareholders' equity in its consolidated balance sheet — was ₹816 crore on 31 March 2026, up 3.4% from ₹789 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹6,193 crore at the 29 October 2026 close.
NEOGEN CHEMICALS's price-to-book (PB) ratio is 7.59 at the 29 October 2026 close: a market capitalisation of ₹6,193 crore divided by shareholders' equity (book value) of ₹816 crore on 31 March 2026. That is a book value of ₹298.12 per share against a share price of ₹2,261.70.
In FY26, NEOGEN CHEMICALS's return on equity (ROE) was 3.6% and its return on capital employed (ROCE) was 8.1%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 4.5% and ROCE 11.1%.
NEOGEN CHEMICALS's book value per share was ₹298.12 on 31 March 2026: shareholders' equity of ₹816 crore divided by the 2.74 crore shares in issue, down 0.4% from ₹299.24 a year earlier. The share price at the 29 October 2026 close was ₹2,261.70.
NEOGEN CHEMICALS's market capitalisation was ₹6,193 crore at the 29 October 2026 close: 2.74 crore shares at ₹2,261.70 each.
No. NEOGEN CHEMICALS had borrowings of ₹1,330 crore on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 1.63. Its cash and current investments were ₹5 crore, so its net debt was ₹1,325 crore.
In 2026, NEOGEN CHEMICALS has declared one dividend: ₹1 with record date 13 August 2026.
NEOGEN CHEMICALS's basic earnings per share (EPS) were ₹10.90 in FY26, against ₹13.20 in FY25. Over the last four quarters (Q2 FY26 to Q1 FY27) they add up to ₹13.29.
NEOGEN CHEMICALS's dividend yield is 0.04% at the 29 October 2026 close: dividends of ₹1 a share that went ex-dividend in the 12 months before that day, divided by the share price of ₹2,261.70. They were ₹1 on 13 August 2026.
NEOGEN CHEMICALS will announce its Q2 FY27 results (July–September 2026) on Saturday, 31 October 2026, the date of the board meeting it has notified to the exchanges.
Promoters held 48.31% of NEOGEN CHEMICALS on 30 September 2026, down 4.70 percentage points from 53.01% the previous quarter and down 2.92 percentage points from 51.23% a year earlier, according to the shareholding pattern filed with NSE.
In FY26, NEOGEN CHEMICALS generated ₹231 crore of cash from operations and spent ₹556 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of −₹787 crore. In FY25 it was −₹122 crore.
NEOGEN CHEMICALS's latest results are for Q1 FY27 (April–June 2026), filed on 24 July 2026: consolidated net profit ₹17.1 crore, up 66.8% from ₹10.3 crore in Q1 FY26; revenue from operations ₹250 crore, up 34.0% year on year.
On 30 September 2026, NEOGEN CHEMICALS's shares were held by promoters 48.31%, foreign portfolio investors (FII/FPI) 4.14%, domestic institutions (DII) 23.48% (including mutual funds at 16.51%) and retail and other non-institutional investors 24.07%. Over the year, FII holding was down 1.01 percentage points from 5.15% and DII holding was down 1.75 percentage points from 25.23%.
In FY26 (April 2025–March 2026), NEOGEN CHEMICALS's consolidated net profit was ₹28.8 crore, down 17.5% from ₹34.8 crore in FY25, on revenue from operations of ₹862 crore (up 10.9%). Over three years, from FY23, net profit was down 42.5%.
In FY26, NEOGEN CHEMICALS earned net profit of ₹28.8 crore on revenue of ₹862 crore, against ₹1,896 crore on ₹14,584 crore for Tata Chemicals. NEOGEN CHEMICALS's operating margin was 12.8% (Tata Chemicals 4.1%) and its return on equity 3.6% (Tata Chemicals −8.9%). At the 29 October 2026 close, NEOGEN CHEMICALS's market capitalisation was ₹6,193 crore against ₹15,388 crore for Tata Chemicals.
On FY26 consolidated figures, against Tata Chemicals, Aether Industries and National Fertilizers: NEOGEN CHEMICALS's operating margin of 12.8% is the second highest of the four (Tata Chemicals 4.1%, Aether Industries 25.6%, National Fertilizers 2.0%; peer average 10.6%); its return on equity of 3.6% is the third highest of the four (Tata Chemicals −8.9%, Aether Industries 9.4%, National Fertilizers 7.6%; peer average 2.7%); its revenue growth over three years of 7.9% a year is the second highest of the four (Tata Chemicals −4.6% a year, Aether Industries 21.2% a year, National Fertilizers −10.1% a year; peer average 2.2% a year).
From NEOGEN CHEMICALS's own consolidated results, balance sheets and shareholding patterns filed with NSE, and NSE prices (the latest used here: the 29 October 2026 close). Ratios are calculated by Alphave from those filings as each answer describes.
Consolidated figures from the company's filings with NSE; prices are NSE closing prices.